Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.

Article  PubMed  PubMed Central  Google Scholar 

Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncology: Official J Am Soc Clin Oncol. 2023;41(6):1265–74.

Article  CAS  Google Scholar 

Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, et al. Idecabtagene Vicleucel in Relapsed and Refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16.

Article  CAS  PubMed  Google Scholar 

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet (London England). 2020;396(10254):839–52.

Article  PubMed  Google Scholar 

Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, Lopez-Corral L, van Aalderen M, Kwon M, Martínez-Cibrian N, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022;6(12):3606–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet (London England). 2021;398(10299):491–502.

Article  CAS  PubMed  Google Scholar 

Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, et al. Axicabtagene Ciloleucel as Second-Line therapy for large B-Cell lymphoma. N Engl J Med. 2022;386(7):640–54.

Article  CAS  PubMed  Google Scholar 

Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91–103.

Article  CAS  PubMed  Google Scholar 

Si Lim SJ, Grupp SA, DiNofia AM. Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68(9):e29123.

Article  PubMed  Google Scholar 

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45–56.

Article  CAS  PubMed  Google Scholar 

Cartron G, Fox CP, Liu FF, Kostic A, Hasskarl J, Li D, Bonner A, Zhang Y, Maloney DG, Kuruvilla J. Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel. Experimental Hematol Oncol. 2022;11(1):17.

Article  CAS  Google Scholar 

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in Children and Young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raje N, Berdeja J, Lin Y, Siegel D. Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, Eyquem J, Zhao Z, Whitlock BM, Miele MM, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Cancer Discov. 2019;568(7750):112–6.

CAS  Google Scholar 

Majzner RG, Mackall CL. Tumor Antigen escape from CAR T-cell therapy. 2018, 8(10):1219–26.

Sterner RC. CAR-T cell therapy: current limitations and potential strategies. Cancer Discov. 2021;11(4):69.

MathSciNet  Google Scholar 

Zhang Q. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead. Blood cancer journal 2020, 2020:1924379.

Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86(24):10024–8.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Pameijer CR, Navanjo A, Meechoovet B, Wagner JR, Aguilar B, Wright CL, Chang WC, Brown CE, Jensen MC. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Ther. 2007;14(1):91–7.

Article  CAS  PubMed  Google Scholar 

Bailey SR, Maus MV. Gene editing for immune cell therapies. Nat Biotechnol. 2019;37(12):1425–34.

Article  CAS  Google Scholar 

Oren R, Hod-Marco M, Haus-Cohen M, Thomas S, Blat D, Duvshani N, Denkberg G, Elbaz Y, Benchetrit F, Eshhar Z, et al. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. J Immunol (Baltimore Md: 1950). 2014;193(11):5733–43.

Article  CAS  Google Scholar 

Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, Scheinberg DA, Brentjens RJ. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia. 2017;31(8):1788–97.

Article  CAS  PubMed  Google Scholar 

Chailyan A, Marcatili P, Tramontano A. The association of heavy and light chain variable domains in antibodies: implications for antigen specificity. FEBS J. 2011;278(16):2858–66.

Article  CAS  PubMed Central  Google Scholar 

Lynn RC, Feng Y, Schutsky K, Poussin M, Kalota A, Dimitrov DS, Powell DJ Jr. High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia. 2016;30(6):1355–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, Albon SJ, Casanovas-Company J, Castro F, Popova B, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25(9):1408–14.

Article  CAS  PubMed  Google Scholar 

Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin cancer Research: Official J Am Association Cancer Res. 2013;19(12):3153–64.

Article  CAS  Google Scholar 

Smith EL, Staehr M, Masakayan R, Tatake IJ, Purdon TJ, Wang X, Wang P, Liu H, Xu Y, Garrett-Thomson SC, et al. Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-Targeted CAR T cell Vector. Mol Therapy: J Am Soc Gene Therapy. 2018;26(6):1447–56.

Article  CAS  Google Scholar 

Ajina A, Maher J. Strategies to address chimeric Antigen receptor Tonic Signaling. Mol Cancer Ther. 2018;17(9):1795–815.

Article  CAS  PubMed Central  Google Scholar 

Calderon H, Mamonkin M, Guedan S. Analysis of CAR-Mediated Tonic Signaling. Methods Mol Biology (Clifton NJ). 2020;2086:223–36.

Article  CAS  Google Scholar 

Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36(8):494–502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pircher M, Schirrmann T, Petrausch U. T Cell Engineering. Progress Tumor Res. 2015;42:110–35.

Article  Google Scholar 

Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius JJW, Sievers SA, Yang S, Kochenderfer JN. Function of Novel Anti-CD19 chimeric Antigen receptors with human variable regions is affected by Hinge and Transmembrane domains. Mol Therapy: J Am Soc Gene Therapy. 2017;25(11):2452–65.

Article  CAS  Google Scholar 

Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M. Hinge and Transmembrane Domains of Chimeric Antigen Receptor regulate receptor expression and signaling threshold. Cells 2020, 9(5).

Dos Santos MH, Machado MP, Kumaresan PR, da Silva TA. Modification of Hinge/Transmembrane and Signal Transduction Domains improves the expression and signaling threshold of GXMR-CAR specific to Cryptococcus spp. Cells 2022, 11(21).

Muller YD, Nguyen DP, Ferreira LMR, Ho P, Raffin C, Valencia RVB, Congrave-Wilson Z, Roth TL, Eyquem J, Van Gool F, et al. The CD28-Transmembrane domain mediates chimeric Antigen receptor heterodimerization with CD28. Front Immunol. 2021;12:639818.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995;181(5):1653–9.

Article  CAS  PubMed  Google Scholar 

Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, et al. Adoptive immunotherapy for indolent non-hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan WK, Williams J, Sorathia K, Pray B, Abusaleh K, Bian Z, Sharma A, Hout I, Nishat S, Hanel W, et al. A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models. Experimental Hematol Oncol. 2023;12(1):79.

Article  CAS